[{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"North China Pharmaceutical Co., Ltd.","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"North China Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"North China Pharmaceutical Co., Ltd. \/ North China Pharmaceutical Co., Ltd."}]

Find Clinical Drug Pipeline Developments & Deals by North China Pharmaceutical Co., Ltd.

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase IV

                          Recipient : Peking University First Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 19, 2021

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Peking Union Medical College Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 08, 2019

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Recipient : Peking Union Medical College Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          October 14, 2011

                          Lead Product(s) : Shenwu

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank